What is MaxCyte's revenue?

MaxCyte (MXCT) generated $32.3M in revenue over the trailing twelve months, down 14.3% year over year.

Is MaxCyte profitable?

MaxCyte is not currently profitable: it reported a net loss of $39.1M over the trailing twelve months, a -121.2% net margin.

What are MaxCyte's profit margins?

Gross margin is 80.5% and operating margin is -141.8%, with a -121.2% net margin.

What is MaxCyte's earnings per share?

MaxCyte's diluted EPS over the trailing twelve months is $-0.37.

Where does MaxCyte's income statement data come from?

Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

MaxCyte MXCT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$33.03M-14.5%	$38.63M-6.4%	$41.29M-6.7%	$44.26M+30.6%
Total cost of revenue	$6.22M-12.4%	$7.1M+49.7%	$4.74M-7.0%	$5.1M+39.8%
Gross profit	$26.8M-15.0%	$31.53M-13.7%	$36.55M-6.7%	$39.16M+29.5%
Gross margin	81.2%-0.5pp	81.6%-6.9pp	88.5%0.0pp	88.5%-0.8pp
Research and development	$20.82M-6.3%	$22.23M-6.7%	$23.82M+22.1%	$19.51M+26.7%
Selling and marketing	$18.92M-29.0%	$26.66M-1.2%	$26.98M+44.6%	$18.65M+43.5%
General and administrative	$28.12M-5.3%	$29.69M-1.2%	$30.07M+16.4%	$25.83M+38.3%
Total operating expenses	$78.7M-4.9%	$82.73M-2.5%	$84.85M+27.5%	$66.52M+37.3%
Operating income	-$51.9M-1.4%	-$51.2M-6.0%	-$48.3M-76.5%	-$27.36M-50.4%
Operating margin	-157.1%-24.6pp	-132.5%-15.6pp	-117%-55.2pp	-61.8%-8.2pp
Other income (expense), net	$7.27M-28.3%	$10.14M-2.3%	$10.38M+174%	$3.79M+489%
Income before income taxes	-$44.63M-8.7%	-$41.06M-8.3%	-$37.92M—	——
Income tax expense	——	——	——	——
Net income	-$44.63M-8.7%	-$41.06M-8.3%	-$37.92M-60.9%	-$23.57M-23.5%
Net margin	-135.1%-28.9pp	-106.3%-14.4pp	-91.8%-38.6pp	-53.3%+3.0pp
Diluted earnings per share	-$0.43-10.3%	-$0.39-5.4%	-$0.37-60.9%	-$0.23-4.5%
EBITDA	-$47.56M-1.4%	-$46.88M-6.2%	-$44.13M-78.9%	-$24.66M-47.1%
EBITDA margin	-144%-22.6pp	-121.4%-14.5pp	-106.9%-51.2pp	-55.7%-6.3pp
EBIT	-$51.9M-1.4%	-$51.2M-6.0%	-$48.3M-76.5%	-$27.36M-50.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about MaxCyte.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's revenue?: MaxCyte (MXCT) generated $32.3M in revenue over the trailing twelve months, down 14.3% year over year.
Is MaxCyte profitable?: MaxCyte is not currently profitable: it reported a net loss of $39.1M over the trailing twelve months, a -121.2% net margin.
What are MaxCyte's profit margins?: Gross margin is 80.5% and operating margin is -141.8%, with a -121.2% net margin.
What is MaxCyte's earnings per share?: MaxCyte's diluted EPS over the trailing twelve months is $-0.37.
Where does MaxCyte's income statement data come from?: Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.